CYP1A1 and neoplasm: In this study, we have evaluated the capability of CYP1A1, 1B1 and 2J2, known to be over-expressed in various tumor types [6], [7], [10], [11], [12], [13] and known to biotransform various drugs [17], [18], [19], [20], to metabolize 5 TKI: dasatinib, imatinib, nilotinib, sunitinib and sorafenib.